Published in Leukemia on April 01, 2005
The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia. Br J Cancer (2005) 1.41
Association of weekend admission with hospital length of stay, time to chemotherapy, and risk for respiratory failure in pediatric patients with newly diagnosed leukemia at freestanding US children's hospitals. JAMA Pediatr (2014) 1.39
Health Care Failure Mode and Effect Analysis: a useful proactive risk analysis in a pediatric oncology ward. Qual Saf Health Care (2006) 1.12
Outcome of pediatric acute myeloid leukemia patients receiving intensive care in the United States. Pediatr Crit Care Med (2014) 1.02
Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia. J Clin Oncol (2015) 1.00
Incidence and predictors of treatment-related mortality in paediatric acute leukaemia in El Salvador. Br J Cancer (2009) 0.93
Transplant-related mortality following allogeneic hematopoeitic stem cell transplantation for pediatric acute lymphoblastic leukemia: 25-year retrospective review. Pediatr Blood Cancer (2013) 0.90
Anti-cancer effects of ginsenoside compound k on pediatric acute myeloid leukemia cells. Cancer Cell Int (2013) 0.89
Pediatric AML: From Biology to Clinical Management. J Clin Med (2015) 0.85
Clinical consequences of hyperglycemia during remission induction therapy for pediatric acute lymphoblastic leukemia. Leukemia (2008) 0.84
Patient and hospital factors associated with induction mortality in acute lymphoblastic leukemia. Pediatr Blood Cancer (2013) 0.79
Early Response to Dexamethasone as Prognostic Factor: Result from Indonesian Childhood WK-ALL Protocol in Yogyakarta. J Oncol (2012) 0.78
Cure trends in acute lymphoblastic leukemia: is it time for a revised concept of cure? Haematologica (2013) 0.75
Randomized double blind trial of ciprofloxacin prophylaxis during induction treatment in childhood acute lymphoblastic leukemia in the WK-ALL protocol in Indonesia. J Blood Med (2013) 0.75
Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells. J Exp Clin Cancer Res (2017) 0.75
The factors affecting early death after the initial therapy of acute myeloid leukemia. Int J Clin Exp Med (2015) 0.75
Intensive serial biomarker profiling for the prediction of neutropenic Fever in patients with hematologic malignancies undergoing chemotherapy: a pilot study. Hematol Rep (2014) 0.75
Image diagnosis: Weber syndrome: a rare presentation of acute leukemia-a case report and review of the literature. Perm J (2015) 0.75
Asparaginase-associated pancreatitis: a study on phenotype and genotype in the NOPHO ALL2008 protocol. Leukemia (2016) 0.75
Decreased relapsed rate and treatment-related mortality contribute to improved outcomes for pediatric acute myeloid leukemia in successive clinical trials. Cancer (2017) 0.75
Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet (1998) 3.91
Contemporary classification of histiocytic disorders. The WHO Committee On Histiocytic/Reticulum Cell Proliferations. Reclassification Working Group of the Histiocyte Society. Med Pediatr Oncol (1997) 3.83
Alternative therapies for the treatment of childhood cancer. N Engl J Med (1998) 2.82
HLH-94: a treatment protocol for hemophagocytic lymphohistiocytosis. HLH study Group of the Histiocyte Society. Med Pediatr Oncol (1997) 2.59
The MLL recombinome of acute leukemias in 2013. Leukemia (2013) 2.55
IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL. Leukemia (2010) 2.17
In vitro cellular drug resistance in children with relapsed/refractory acute lymphoblastic leukemia. Blood (1995) 2.00
Extramedullary infiltrates at diagnosis have no prognostic significance in children with acute myeloid leukaemia. Leukemia (2001) 1.84
Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands. Leukemia (2004) 1.71
Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia. J Clin Oncol (2003) 1.67
X-linked lymphoproliferative disease: twenty-five years after the discovery. Pediatr Res (1995) 1.65
The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia. Crit Rev Oncol Hematol (2004) 1.65
The association of eosinophilia with lymphoblastic leukaemia or lymphoma: a study of seven patients. Br J Haematol (1980) 1.63
Overexpression of the HER-2 oncogene does not play a role in high-grade osteosarcomas. Eur J Cancer (2004) 1.58
Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples. Leukemia (2006) 1.53
Overview: chemotherapy for retinoblastoma: an expanding area of clinical research. Med Pediatr Oncol (2002) 1.51
Choroid plexus tumours. Br J Cancer (2002) 1.50
Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. Leukemia (2005) 1.50
Plasma IL-8 and IL-6 levels can be used to define a group with low risk of septicaemia among cancer patients with fever and neutropenia. Br J Haematol (1999) 1.46
Vincristine revisited. Crit Rev Oncol Hematol (1999) 1.46
Long-term results of Dutch Childhood Oncology Group studies for children with acute lymphoblastic leukemia from 1984 to 2004. Leukemia (2009) 1.45
The prognosis of oncologic patients in the pediatric intensive care unit. Intensive Care Med (1996) 1.45
Immunoglobulin kappa deleting element rearrangements in precursor-B acute lymphoblastic leukemia are stable targets for detection of minimal residual disease by real-time quantitative PCR. Leukemia (2002) 1.42
The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia. Br J Cancer (2005) 1.41
Allogeneic bone marrow transplantation for juvenile myelomonocytic leukemia: a single center experience of 23 patients. Bone Marrow Transplant (2005) 1.41
Immunophenotypic modulation in childhood precursor-B-ALL can be mimicked in vitro and is related to the induction of cell death. Leukemia (2005) 1.39
Low efficacy of methotrexate in childhood acute myeloid leukemia (AML): single-agent therapeutic window study in relapsed AML. Pediatr Blood Cancer (2006) 1.39
Cushing syndrome as a presenting symptom of renal tumors in children. Pediatr Blood Cancer (2009) 1.39
[A cavernous haemangioma of the colon as the cause of rectal bleeding in childhood]. Ned Tijdschr Geneeskd (2004) 1.39
Langerhans cell histiocytosis--clinical and epidemiological aspects. Br J Cancer Suppl (1994) 1.38
Gene expression profiling in MDS and AML: potential and future avenues. Leukemia (2011) 1.38
Prognostic significance of molecular-cytogenetic abnormalities in pediatric T-ALL is not explained by immunophenotypic differences. Leukemia (2007) 1.36
Profiling of high-grade central osteosarcoma and its putative progenitor cells identifies tumourigenic pathways. Br J Cancer (2009) 1.35
Specific sequelae after Fontan operation at mid- and long-term follow-up. Arrhythmia, liver dysfunction, and coagulation disorders. J Thorac Cardiovasc Surg (1993) 1.29
Psychological adaptation and social support of parents of pediatric cancer patients: a prospective longitudinal study. J Pediatr Psychol (2001) 1.28
The epidemiology of Langerhans cell histiocytosis. Hematol Oncol Clin North Am (1998) 1.28
Precursor-B-ALL with D(H)-J(H) gene rearrangements have an immature immunogenotype with a high frequency of oligoclonality and hyperdiploidy of chromosome 14. Leukemia (2001) 1.28
In vitro drug sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions. Blood (1990) 1.26
Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia. Lancet (1991) 1.26
Leukaemia incidence and survival in children and adolescents in Europe during 1978-1997. Report from the Automated Childhood Cancer Information System project. Eur J Cancer (2006) 1.24
Obesity after successful treatment of acute lymphoblastic leukemia in childhood. Pediatr Res (1995) 1.24
The heterogeneity of pediatric MLL-rearranged acute myeloid leukemia. Leukemia (2011) 1.21
Role of folylpolyglutamate synthetase and folylpolyglutamate hydrolase in methotrexate accumulation and polyglutamylation in childhood leukemia. Blood (1999) 1.20
Co-infusion of ex vivo-expanded, parental MSCs prevents life-threatening acute GVHD, but does not reduce the risk of graft failure in pediatric patients undergoing allogeneic umbilical cord blood transplantation. Bone Marrow Transplant (2010) 1.20
Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML. Leukemia (2008) 1.18
Biology of Langerhans cells and Langerhans cell histiocytosis. Int Rev Cytol (2006) 1.17
High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia. Results of protocol ALL VI from the Dutch Childhood Leukemia Study Group. J Clin Oncol (1996) 1.16
Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL. Leukemia (2002) 1.16
Vincristine pharmacokinetics after repetitive dosing in children. Cancer Chemother Pharmacol (1999) 1.14
Chemosensitivity of glioma cells in vitro: a meta analysis. J Cancer Res Clin Oncol (1999) 1.14
Slight cognitive impairment and magnetic resonance imaging abnormalities but normal school levels in children treated for acute lymphoblastic leukemia with chemotherapy only. J Pediatr (2001) 1.14
Pharmacokinetic, pharmacodynamic and intracellular effects of PEG-asparaginase in newly diagnosed childhood acute lymphoblastic leukemia: results from a single agent window study. Leukemia (2008) 1.12
How to improve the search for an unrelated haematopoietic stem cell donor. Faster is better than more! Bone Marrow Transplant (2005) 1.11
Radiation therapy and survival in choroid plexus carcinoma. Lancet (1999) 1.11
Human bone marrow cells positive for terminal deoxynucleotidyl transferase (TdT), HLA-DR, and a T cell marker may represent prothymocytes. J Immunol (1985) 1.11
TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia. Blood (2000) 1.10
High burden of late effects after haematopoietic stem cell transplantation in childhood: a single-centre study. Bone Marrow Transplant (2009) 1.09
Cytogenetic heterogeneity in t(11;19) acute leukemia: clinical, hematological and cytogenetic analyses of 48 patients--updated published cases and 16 new observations. Leukemia (1993) 1.08
Clinical aspects of Langerhans cell histiocytosis. Hematol Oncol Clin North Am (1998) 1.08
Cytologic "differentiation" in childhood rhabdomyosarcomas following polychemotherapy. Hum Pathol (1984) 1.07
A lack of neuroblastoma in Down syndrome: a study from 11 European countries. Cancer Res (1998) 1.07
EVI1 overexpression in distinct subtypes of pediatric acute myeloid leukemia. Leukemia (2010) 1.07
Prevalence and prognostic value of IDH1 and IDH2 mutations in childhood AML: a study of the AML-BFM and DCOG study groups. Leukemia (2011) 1.07
Outcome in children with Down's syndrome and acute lymphoblastic leukemia: role of IKZF1 deletions and CRLF2 aberrations. Leukemia (2012) 1.06
Familial clustering of Langerhans cell histiocytosis. Br J Haematol (1999) 1.06
Haematopoietic stem cell transplantation trends in children over the last three decades: a survey by the paediatric diseases working party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant (2007) 1.05
Acute adrenal insufficiency after discontinuation of inhaled corticosteroid therapy. Lancet (1992) 1.05
Multiple rearranged immunoglobulin genes in childhood acute lymphoblastic leukemia of precursor B-cell origin. Leukemia (1991) 1.03
Molecular cytogenetic and clinical findings in ETV6/ABL1-positive leukemia. Genes Chromosomes Cancer (2001) 1.03
The effect of chemotherapy on the growing skeleton. Cancer Treat Rev (2000) 1.03
Bone mineral density, body composition, and height in long-term survivors of acute lymphoblastic leukemia in childhood. Med Pediatr Oncol (2000) 1.03
Microenvironmental studies of pre-B and B cell development in human and mouse fetuses. J Immunol (1982) 1.03
Adenovirus infection in children after allogeneic stem cell transplantation: diagnosis, treatment and immunity. Bone Marrow Transplant (2005) 1.02
Quality of life in bone tumor patients comparing limb salvage and amputation of the lower extremity. J Surg Oncol (1992) 1.02
Hemopoiesis in human fetal and embryonic liver. Microsc Res Tech (1997) 1.02
Glucocorticoid receptor alpha, beta and gamma expression vs in vitro glucocorticod resistance in childhood leukemia. Leukemia (2004) 1.01
Magnetic resonance imaging of the brain and neuropsychological evaluation in children treated for acute lymphoblastic leukemia at a young age. Am J Pediatr Hematol Oncol (1993) 1.01
The presence of cytokines in Langerhans' cell histiocytosis. J Pathol (1996) 1.01
Low frequency of DNMT3A mutations in pediatric AML, and the identification of the OCI-AML3 cell line as an in vitro model. Leukemia (2011) 1.01
Preemptive alloimmune intervention in high-risk pediatric acute lymphoblastic leukemia patients guided by minimal residual disease level before stem cell transplantation. Leukemia (2010) 1.00
Aurora kinases in childhood acute leukemia: the promise of aurora B as therapeutic target. Leukemia (2012) 1.00
Myeloid leukemia in children 4 years or older with Down syndrome often lacks GATA1 mutation and cytogenetics and risk of relapse are more akin to sporadic AML. Leukemia (2007) 1.00
TET2 mutations in childhood leukemia. Leukemia (2010) 0.99